Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Retained Earnings (2020 - 2025)

Universe Pharmaceuticals' Retained Earnings history spans 6 years, with the latest figure at -$1.8 billion for Q3 2025.

  • On a quarterly basis, Retained Earnings rose 82.17% to -$1.8 billion in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.8 billion, a 82.17% increase, with the full-year FY2025 number at -$1.8 billion, up 82.17% from a year prior.
  • Retained Earnings hit -$1.8 billion in Q3 2025 for Universe Pharmaceuticals, up from -$10.2 billion in the prior quarter.
  • Over the last five years, Retained Earnings for UPC hit a ceiling of $26.8 million in Q1 2022 and a floor of -$10.2 billion in Q3 2024.
  • Historically, Retained Earnings has averaged -$1.5 billion across 5 years, with a median of -$1.6 million in 2022.
  • Biggest five-year swings in Retained Earnings: tumbled 704170.53% in 2024 and later surged 82.17% in 2025.
  • Tracing UPC's Retained Earnings over 5 years: stood at $2.1 million in 2021, then plummeted by 179.79% to -$1.7 million in 2022, then grew by 13.35% to -$1.4 million in 2023, then tumbled by 704170.53% to -$10.2 billion in 2024, then surged by 82.17% to -$1.8 billion in 2025.
  • Business Quant data shows Retained Earnings for UPC at -$1.8 billion in Q3 2025, -$10.2 billion in Q3 2024, and -$2.1 million in Q1 2024.